Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19507038 | 0.86 | HCAR3 (0.37) | HCAR3HCAR2OPRM1DAO | |
| SCHEMBL23878712 | 0.82 | HCAR3 (0.35) | HCAR3HCAR2DAO | |
| SCHEMBL2273108 | 0.78 | DRD2 (0.50) | DRD2SIGMAR1HCAR3HCAR2OPRM1 | |
| SCHEMBL9528058 | 0.69 | OPRM1 (0.39) | DRD2SIGMAR1HCAR3HCAR2OPRM1 | |
| SCHEMBL1401191 | 0.68 | OPRM1 (0.50) | DRD2SIGMAR1OPRM1 | |
| SCHEMBL5696483 | 0.68 | DRD2 (0.36) | DRD2SIGMAR1OPRM1 | |
| Hydrochloric Acid SCHEMBL9528146 | 0.68 | OPRM1 (0.38) | DRD2SIGMAR1HCAR3HCAR2OPRM1 | |
| SCHEMBL5460312 | 0.68 | DRD2 (0.36) | DRD2SIGMAR1OPRM1 | |
| SCHEMBL613058 | 0.67 | DRD2 (0.66) | DRD2SIGMAR1OPRM1GABRDGABRA1 | |
| SCHEMBL17438743 | 0.66 | OPRM1 (0.31) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185168-A1 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1736474-A1 | PIPERIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185168-A1 | Piperidine derivatives | GRIN2C, GRIN1, GRIN3A | DRD2 96/4885SIGMAR1 134/4885HCAR3 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.